Injectable anifrolumab for polymyositis or dermatomyositis
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This study tests a new injectable medicine (anifrolumab) added to your usual treatments for polymyositis or dermatomyositis. It may help reduce disease activity if you have moderate to severe symptoms and are already on stable therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of polymyositis or dermatomyositis (moderate to severe).
- You must be on a stable dose of your current myositis medicines (like prednisone).
- You cannot have certain other muscle diseases, cancer, or serious infections.
- Women who can become pregnant must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
This trial tests a new drug called nerandomilast in people with active inflammatory muscle disease (myositis) that is not well controlled with current treatments. It aims to see if the drug can improve muscle strength and overall disease activity.
This study tests whether an intravenous medicine called anifrolumab can safely improve active systemic lupus (SLE) in children. If you qualify, you may receive the study treatment and be closely monitored for safety and lupus symptoms.
This study lets people who finished a previous anifrolumab (Saphnelo) trial and saw benefits continue getting the treatment. It aims to see how well the drug works over a longer time.
This study tests an experimental drug called anifrolumab, which is given as an injection or infusion, to see how it works in people with active lupus. It may help reduce lupus symptoms by targeting the immune system.
This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.
Hear when a new Polymyositis, Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.